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Because nonsteroidal anti-inﬂammatory drugs (NSAIDs) inhibit tumor growth in vitro, we investigated the association between
NSAIDs and melanoma to determine if there was epidemiologic evidence of a chemopreventive eﬀect from these medications.
Three hundred twenty-seven subjects with incident melanoma and 119melanoma-free controls completed a structured interview
assessingmelanomarisk factors. The unadjusted odds ratio (OR) for use of nonaspirin NSAIDs was 0.58 (95% CI 0.31–1.11),in a
comparison of subjects with melanoma to controls. After adjustment for melanoma risk factors, the OR was 0.71 (95% CI 0.23–
2.02).Aspirin usershadanunadjusted ORof0.85 (95%CI0.45–1.69)andanadjusted ORof1.45(95%CI0.44–4.74).In thispilot
study, we found no evidence of a signiﬁcantassociationbetween analgesicuse and melanomarisk when potential confounders are
assessed. Based on conﬂicting reports in the literature, meta-analysis may be appropriate.
1.Introduction
Melanoma is a potentially fatal tumor that continues to
increase in incidence despite public education measures to
limitsunexposure [1].Chemopreventionhasbeenidentiﬁed
as an important strategy for reducing melanoma inci-
dence [2]. Among the candidate agents, nonsteroidal anti-
inﬂammatory drugs (NSAIDs) have been shown to aﬀect
the mechanisms of cellular damage caused by ultraviolet
radiation [3]. Expression of cyclooxygenase-2 (COX-2), the
primary pharmacologic target of NSAIDs, has been reported
in up to 93% of melanomas [4]. In addition, in vitro
and animal studies have demonstrated a protective eﬀect
of NSAIDs against melanoma; [4–6] however, studies in
humans have had conﬂicting results [7–9].
Using acase-control design, we tested the hypothesis that
NSAIDsconvey a chemoprotective eﬀect against melanoma.
2.Methods
The Genes, Environment, and Melanoma (GEM) study is
a multicenter case-control study investigating heredity and
environment in melanoma. A full description of the GEM
study design has been published separately [10–12]. In this
report, only the University of Michigan subjects were used,
since supplemental data regarding medication usage was not
collected from other centers.
Individuals with a ﬁrst primary invasive melanoma
diagnosed in the year 2000 and individuals with a second or
higher order invasive primary melanoma diagnosed between
January 1, 2000, and August 31, 2003, were eligible for
participation. At the University of Michigan site, subjects
with aﬁrst primary melanoma insitu diagnosed in2000were
alsoenrolled.Thissitealsoenrolledspousesofthemelanoma
subjects to act as controls. The inclusion criteria for controls
were a current spousal relationship to a melanoma subject
and willingness to provide informed consent to participate.
Spouses were excluded from participation as controls if they
had a personal history of melanoma. The current analysis
is restricted to cases diagnosed with ﬁrst primary invasive
melanoma or melanoma in situ.
Participants provided written informed consent at the
time of enrollment. The protocol was approved by the
Institutional Review Board at the University of Michigan.
Subjects completed an interview assessing personal and
familyhistoryofcancer,skinphenotype,medicationuse,and2 Journal of Skin Cancer
Table 1: Demographic characteristics.
Characteristic Melanoma cases Controls P-value
All subjects—no 327 119
Sex—no (%)
Male 162 (49.5%) 41 (34.5%) .0047
Female 165 (50.5%) 78 (65.6%)
Age—yr (median (interquartile range)) 53 (41–66) 56 (46–66)
Family history melanoma—no(%) 51 (15.8%) 11 (9.5%) .0926
Skin Color—no (%)
Light 287 (88.9%) 49 (69.0%) <.0001
Dark 36 (11.1%) 22 (31.0%)
Number of moles on back (median
(interquartile range)) 10 (4–29.5) 5 (1–12)
Current medication use—no (%) 217 (66.4%) 91 (76.5%) .0413
Past medication use—no (%) 106 (32.9%) 46 (40.0%) .1918
Comorbidities—no (%) 168 (50.9%) 70 (58.3%) .1634
Cardiovascular disease—no (%) 37 (8.2%) 9 (7.5%) .7965
Musculoskeletal pain—no (%) 22 (4.9%) 18 (15.0%) .0001
SD Standard deviation. P-values for categorical variables are from Mantel-Haenszel χ2t e s t .
comorbidities. To assess past and current use of analgesics,
they were asked to recall medications used on a daily basis
for at least three months.
Statistical analyses were performed using SAS software
(version 9.1). Contingency tables were used to assess the
crude associations between medication use and melanoma
risk. Fisher’s exact test was used to determine P-values when
cells contained counts of less than 10. Unconditional logistic
regression was used to assess the association between med-
ication use and melanoma risk, to adjust for confounding,
andtoidentify any potentialeﬀectmodiﬁcation. Allreported
P values are two-sided.
Potential variables evaluated for the multivariate model
includedage, gender, family history ofmelanoma, skin color,
hair color, eye color, history of severe sunburn, history of
cardiovascular disease, history of a musculoskeletal pain
condition, tendency of skin to burn, tendency of skin to tan,
age at ﬁrst sunburn, number of moles on the back, smoking
history, history of other medical diagnoses (yes/no), and
statinuse.Covariates wereincludedintheinitialmultivariate
model if the addition of that covariate to the univariate
model of analgesic use and melanoma risk resulted in a 10%
or greater change in the odds ratio. These covariates were
then removed from the saturated multivariate model in a
stepwise fashion to optimize the ﬁt to the data as determined
by the AIC.
3.Results
Sevenhundredtwenty-eightindividualswereapproachedfor
study participation at the University of Michigan. Of these,
509 (69.8%) completed the telephone interview. Melanoma
patients accounted for 390 of these subjects; the remaining
119 were melanoma-free spouses of the patients. Among the
melanomasubjects,104had insitu melanoma,223hadaﬁrst
(single primary) melanoma, and 63 had a second or higher-
order (multiple primary) melanoma. In this analysis, indi-
viduals with multiple primary melanomas were excluded, as
we could not adjust for selection bias based on survival from
the ﬁrst primary melanoma. Demographic characteristics
are described in Table 1, and results are summarized in
Table 2.D u et ot h ed i ﬀerences in gender and age between
the melanoma and control groups, these variables were
empirically included in the multivariate models. Covariates
intheﬁnalmodelswereage,gender,skincolor,familyhistory
of melanoma, and number of moles on the back.
3.1. Aspirin. Regular use of aspirin was reported by 10.9% of
controls. Current or past use of aspirin was associated with
an unadjusted odds ratio of 0.85 (95% CI 0.43–1.69). The
odds ratio was 1.45 (95% CI 0.44–4.74) in a multivariate
model adjusted for age, gender, skin color, family history
of melanoma, and number of moles. The number of moles
had the most signiﬁcant eﬀect on the adjusted odds ratio.
Restrictingtheanalysis tocurrentusersorthosewithinvasive
melanoma yielded similar results. Due to small numbers of
subjects, past use could not be evaluated. Subjects with in
situ melanoma were more likely to take aspirin than those
with invasive disease, but this diﬀerence was not statistically
signiﬁcant (OR 0.615; 95% CI 0.29–1.31).
3.2. Nonaspirin NSAIDs. Approximately 14% of control
subjects reported regular use of nonaspirin NSAIDs in our
study. The unadjusted odds ratio for melanoma risk with
any use of nonaspirin NSAIDs was 0.58 (95% CI 0.31–1.11),
and the adjusted odds ratio was 0.71 (95% CI 0.23–2.02).
Covariates in the multivariate model were the same as in
the aspirin model. The addition of aspirin use to the model
did not aﬀect the odds ratio, and results were similar when
restricted to invasive melanoma. Control subjects were moreJournal of Skin Cancer 3
Table 2: Analgesic use and risk of ﬁrst primary invasive or In situ melanoma.
Exposure Patients Controls Total Crude OR (95% CI) Adjusted OR (95% CI)
Ever use of aspirin:
Yes 31 13 44 0.854 (0.431–1.693) 1.447 (0.442–4.736)
No 296 106 402
Ever use of nonaspirin
NSAIDs:
Yes 29 17 46 0.584 (0.308–1.107) 0.710 (0.234–2.024)
No 298 102 400
Ever use of acetaminophen:
Yes 6 3 9 0.723 (0.178–2.937) Not assessed
No 321 116 437
OR Odds ratio; CI Conﬁdence interval; NSAIDs Nonsteroidal anti-inﬂammatory drugs.
likely to be current users of NSAIDs(OR 0.45; 95% CI 0.23–
0.88); however, this association was no longer signiﬁcant
when adjusted for covariates (OR 0.55; 95% CI 0.19–1.58).
Past use was not associated with a decreased melanoma risk.
NSAID use in subjects with in situ disease was similar to use
in those with invasive melanoma.
3.3.COX-2 Speciﬁc Inhibitors. Approximately9%ofcontrols
reported regular use of COX-2 inhibitors. In an exploratory
analysis, thecrudeoddsratio formelanoma in usersofCOX-
2-inhibitors was 0.61 (95% CI 0.28–1.31), and the adjusted
odds ratio was 0.42 (95% CI 0.14–1.27).
3.4. Acetaminophen. In order to assess whether the eﬀects
of NSAIDs were due to the medical indication rather
than the mechanism of action, we evaluated the eﬀect of
acetaminophen on melanoma risk. Due to small numbers of
users (2.5% of controls), Fisher’s exact test was performed
and yielded a two-sided P-value of .72.
4.Discussion
Our results suggest that aspirin and nonaspirin NSAIDs
are not associated with a durable large reduction in risk
of melanoma once potential confounders are taken into
account. A small beneﬁcial eﬀect of these medications may
be seen in a larger study and cannot be excluded. We were
unable to fully assess the eﬀects of COX-2 speciﬁc inhibitors
or acetaminophen due to small numbers of regular users in
our study.
The eﬀect of NSAIDS on melanoma has been assessed
in four other publications. The ﬁrst describes a case-control
study of 110 women with melanoma and 609 matched
controls [7]. The relative risk of melanoma in women taking
NSAIDs was 0.45 (95% CI 0.22–0.92). Our study builds on
this result with the inclusion of men, an increased number
of melanoma cases, and assessment of additional covariates.
The second study investigated the eﬀects of NSAIDs in indi-
viduals who had previously had melanoma [13]. Individuals
taking COX inhibitors were less likely to have new primary
melanoma, melanoma recurrence, or melanoma metastasis.
Our study takes this question from a secondary/tertiary
prevention setting to a primary prevention setting. The
third study linked NSAID use in the Vitamins and Lifestyle
(VITAL) study to the NCI Surveillance, Epidemiology, and
End Results registry [9]. These investigators found no
association between NSAID use and melanoma risk. The
number of cases in this study is similar to ours; however,
many had in situ rather than invasive melanomas. Our study
expands uponthisresult by using a largernumberofinvasive
melanoma cases and adding data on number of moles,
which was the most signiﬁcant covariate in our analysis. The
fourth study assessed this question in the Dutch PHARMO
pharmacy database and the PALGA pathology database [8].
They found a 46% reduction in melanoma risk for women
who had continuous use of aspirin (OR 0.54, 95% CI 0.30–
0.99). Our work adds melanoma risk factors, which can act
as potential confounders.
Our study has several limitations. Unfortunately, we
could not validate reports of medication use with prescrip-
tion records in our study, as many NSAIDs are dispensed
over the counter, and use of these medications is not always
accurately collected in the medical record. Sun exposure
could not be assessed as a potential confounder due to a lack
of a simple, validated measure of this risk factor. However,
we did evaluate self-reported history of severe sunburns,
age at ﬁrst sunburn, and tendency to burn as potential
confounders; these did not have a signiﬁcant eﬀect on the
odds ratios. Selection bias may be present in the control
group, as not all spouses of melanoma subjects participated.
Data are not available on nonconsenting spouses, so we
are unable to assess whether the participating spouses were
representative of the potential control population as a
whole. Additionally, the odds ratios may be attenuated by
overmatching of spouse controls, who may resemble the
cases more than individuals in the general population.
In summary, in our pilot study we found no signiﬁcant
association between analgesic use and melanoma risk when
potential confounders are assessed. Based on the conﬂicting
data for this question, evaluation in a larger cohort that
also allows for assessment of potential confounders or meta-
analysis may be appropriate.4 Journal of Skin Cancer
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